700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Original Articles Open Access
A series of novel hybrid compounds of imidazopyridine and quinoline/carbazole derivatives has been prepared and evaluated in vitro against a panel of four human tumor cell lines(viz., cervical HeLa, breast MDA-MB-231, renal ACHN and colon HCT-15). Among them imidazopyridine-quinoline hybrid compounds, 3-(3-benzylimidazo[1,2- a]pyridine-2-yl)-2-chloro-6-methoxyquinoline (8) and 2-chloro-6-methoxy-3-(3-(4-methylbenzylimidazo[1,2- a]pyridine-2-yl)-quinoline (12) showed potent anticancer activity with the IC50 values of(0.34; 0.32; 0.39; 0.31) and (0.35; 0.29; 0.34; 0.30) respectively, 12 being the best among all the compounds synthesized In case of imidazopyridine-carbazole hybrid compounds, 3-(3-benzylimidazo[1,2-a]pyridine-2-yl)-9-ethyl-9H-carbazole(13) showed best activity with the IC50 value of (0.37; 0.41; 0.39; 0.30) followed by compound 9-ethyl-3-(3-4- methylbenzyl)imidazo[1,2-a]pyridine-2-yl)9H-carbazole (17)with the IC50 value of (0.55; 0.49; 0.60; 0.56). This preliminary study discovered that the imidazopyrine scaffold hybridized with quinoline or carbazole could be a good pharmacophore for finding novel and potent anticancer agents.
To read the full article Peer-reviewed Article PDF
Author(s): Sangeetha Meenakshisundaram Manoj Manickam and Venkateswaran Vinayagam
Hybrid, imidazopyridine, quinoline, carbazole, anticancer activity., anticancer activity